The University of Queensland

Other

Robert C Reid

David P Fairlie

Ligong Liu

Jacky Yung Suen

Mei Kwan Yau

Karl Schafer

Ross Peter McGeary

Karl Hansford

Lindsay Charles Brown

Ross Brinkworth

Doug Bergman

John Abbenante

Robert Dancer

Peter Hunt

Rink-Jan Lohman

Jennifer Martin

Darren March

Abishek Venkatasubramanian Iyer

Christopher I Clark

Martin J Stoermer

Mei-Kwan Yau

Junxian Lim

Bronwyn Garnham

David Fairlie

The present invention provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for therapies such as metabolic syndrome, obesity, type II diabetes, fibrosis and cardiovascular diseases, whether they are used alone or in combination with other treatment modalities. 

Modulators of protease activated receptors

The present application provides novel compounds of the Formula (I), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of&#x2014;or susceptible to&#x2014;a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity.

Heterocyclic compounds that modulate C3a receptors and their use in the treatment or prevention of inflammatory diseases, infectious diseases, cancers, metabolic disorders, obesity, type 2 diabetes, metabolic syndrome and associated cardiovascular diseases are described. The use of the compounds in stimulating or suppressing an immune response is also described together with pharmaceutical compositions comprising the compounds or their pharmaceutically acceptable salts.

Modulators of C3a receptors

The present invention provides novel compounds of the Formula (1), pharmaceutical compositions comprising such compounds and methods for using such compounds as tools for biological studies or as agents or drugs for modulating Protease Activated Receptor-2 (PAR2) and for treating a subject at risk of&#x2014;or susceptible to&#x2014;a disease or disorder, or having a disease or disorder associated with undesirable PAR2 activity. 

Modulations of protease activated receptors

The present invention relates generally to amino acid derivatives and to methods of making the same. In particular, the invention relates to compounds bearing a stereochemical identity, that is, the same stereochemistry, with the chiral &#x3b1;-carbon of D-&#x3b1;-amino acids and their use in methods of therapy, including the treatment of inflammatory diseases, and to compositions and enantiomeric mixtures containing them.

Compounds and inhibitors of phospholipases

HIV protease inhibitors

A concrete floor system includes undulating sheet metal formwork for forming concrete slabs with one or more concrete ribs. The system also provides a unique type of bar chair which allows reinforcement in the form of steel rods, for example, to be dropped in place, thereby minimizing the labor required in installing the formwork.

Concrete floor system

Growing community of inventors

Chelmer, Australia

Robert C Reid